Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × BRCA-Mutated Breast Carcinoma × famitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 4 Breast Neoplasms 4 Small Cell Lung Carcinoma 2 Ovarian Neoplasms 2 Cervical Cancer Metastatic 2 Thyroid Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Melanoma 1 Esophageal Squamous Cell Carcinoma 1 Disease Progression 1 Carcinoma, Non-Small-Cell Lung 1 BRCA-Mutated Breast Carcinoma 1

Interventions

famitinib 1 camrelizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06516289 2024-12-12

Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab

Fudan University

Phase 2 Recruiting

BRCA-Mutated Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡